Fludeoxyglucose (18F) FDG
Image for illustration purposes only.
Radiopharmaceutical used in PET/CT procedures in Oncology, Cardiology and Neurology.
Manufactured and distributed by:
São José do Rio Preto/SP location (M.S 1.3030.0001) Flutep® Fludeoxyglucose (18F)
- Presentation: shielded packaging containing 1 multidose vial.
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
- Ingredients: Each vial of radiopharmaceutical contains: Fludeoxyglucose (18F) ……………. 10 mCi
- Excipients: 0.9% Sodium Chloride and water for injection.
- Physical half-life: 109.7 minutes.
- Indication: Imaging diagnosis using Positron Emission Tomography (PET and PET/CT) for oncological, brain and cardiac studies.
Itupeva/SP location (M.S 1.3030.0001) – Flutep® Fludeoxyglucose (18F)
- Presentation: shielded packaging containing 1 multidose vial.
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
- Ingredients: Each vial of radiopharmaceutical contains: Fludeoxyglucose (18F) ……………. 10 mCi
- Excipients: 0.9% Sodium Chloride and water for injection.
- Physical half-life: 109.7 minutes.
- Indication: Imaging diagnosis using Positron Emission Tomography (PET and PET/CT) for oncological, brain and cardiac studies.
Duque de Caxias/RJ (M.S 1.8108.0001) - Fluesocil® Fludeoxyglucose (18F)
- Presentation: shielded packaging containing 1 multidose vial.
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
-
Ingredients: Each vial may contain up to 10 mL of:
Fluesocil® 370: 370 MBq (10 mCi) of fludeoxyglucose (18F)
Fluesocil® 925: 925 MBq (25 mCi) of fludeoxyglucose (18F)
Fluesocil® 1739: 1739 MBq (47 mCi) of fludeoxyglucose (18F)
Fluesocil® 2923: 2923 MBq (79 mCi) of fludeoxyglucose (18F)
Fluesocil® 4625: 4625 MBq (125 mCi) of fludeoxyglucose (18F)
Fluesocil® 7104: 7104 MBq (192 mCi) of fludeoxyglucose (18F)
Fluesocil® 10730: 10730 MBq (290 mCi) of fludeoxyglucose (18F)
Fluesocil® 15984: 15984 MBq (432 mCi) of fludeoxyglucose (18F)
Fluesocil® 23680: 23680 MBq (640 mCi) of fludeoxyglucose (18F)
Fluecosil® 34891: 34891 MBq (943 mCi) of fludeoxyglucose (18F)
Fluesocil® 51282: 51282 MBq (1386 mCi) of fludeoxyglucose (18F) - Excipients: 0.9% Sodium Chloride and water for injection.
- Physical half-life: 109.7 minutes.
- Indication: Imaging diagnosis using Positron Emission Tomography (PET and PET/CT) for oncological, brain and cardiac studies.
Curitiba/PR location (M.S 1.9777.0001) Curitiba/PR (M.S 1.9777.0001) fludeoxyglucose (18F)
- Presentation: Packaging with 1 vial containing 0.1 to 12 mL containing 1850 mBg/mL (50mCi/mL) to 16,280 mBg/mL (440 mCi/mL)* of fludeoxyglucose 18F .
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
- Ingredients: Each vial with injectable sterile solution contains: fludeoxyglucose 18F ……………. 0.1 to 5,280 mCi.
- Physical half-life: 109.7 minutes.
- Indication: Imaging diagnosis using Positron Emission Tomography (PET and PET/CT) for oncological, brain and cardiac studies.
Vitória de Santo Antão/PE location (M.S 1.3030.0001) - Flutep® fludeoxyglucose (18F)
- Presentation: shielded packaging containing 1 multidose vial.
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
- Ingredients: Each vial of radiopharmaceutical contains: Fludeoxyglucose (18F) ……………. 10 mCi
- Excipients: 0.9% Sodium Chloride and water for injection.
- Physical half-life: 109.7 minutes.
- Indication: Imaging diagnosis using Positron Emission Tomography (PET and PET/CT) for oncological, brain and cardiac studies.
Porto Alegre/RS location, in partnership with InsCer – PUCRS, (M.S 1.9961.0001.001) - Glicocer® fludeoxyglucose (18F)
- Presentation: shielded packaging containing 1 multidose vial.
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
-
Ingredients: Each vial may contain up to 12 mL of:
Glicocer®: 370 MBq (10 mCi) of fludeoxyglucose (18F)
Glicocer®: 740 MBq (20 mCi) of fludeoxyglucose (18 F)
Glicocer®: 1.110 MBq (30 mCi) of fludeoxyglucose (18F)
Glicocer®: 1.480 MBq (40 mCi) of fludeoxyglucose (18 F)
Glicocer®: 1.850 MBq (50 mCi) of fludeoxyglucose (18F)
Glicocer®: 2.220 MBq (60 mCi) of fludeoxyglucose (18 F)
Glicocer®: 2.590 MBq (70 mCi) of fludeoxyglucose (18F)
Glicocer®: 2.960 MBq (80 mCi) of fludeoxyglucose (18 F)
Glicocer®: 3.330 MBq (90 mCi) of fludeoxyglucose (18F)
Glicocer®: 3.700 MBq (100 mCi) of fludeoxyglucose (18 F)
Glicocer®: 4.070 MBq (110 mCi) of fludeoxyglucose (18F). - Excipients: Water for injection and ethyl alcohol
- Physical half-life: 109.8 minutes.
- Indication: Imaging diagnosis using Positron Emission Tomography (PET and PET/CT) for oncological, brain and cardiac studies.
R2Pharma products are available only by means of medical prescription from a licensed physician.
IF SYMPTOMS PERSIST, A DOCTOR SHOULD BE CONSULTED.
Contraindications, warnings, adverse reactions, drug interactions, precautions and posology: refer to package leaflet.
The content of this page is destined to health professionals.